Abstracts tagged "Myocarditis"

Abstract Number: 0313 • ACR Convergence 2024
Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Sehreen Mumtaz¹, Jayesh Valecha², Andy Abril³, Florentina Berianu³, Benjamin Wang⁴, Ronald Butendieck⁴, anushka Irani², carolyn mead harvey² and Vikas Majithia², ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Jacksonville, FL
Background/Purpose: Sarcoidosis, characterized by non-necrotizing granulomatous inflammation, is a multisystem disease with an unpredictable disease spectrum. An estimated 5% of sarcoidosis patients have clinically evident…
Abstract Number: 0322 • ACR Convergence 2024
Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging
Julie Paik¹, Shadi Ayoumi², Ghazal Zandieh², Cody Calhoun², Caoilfhionn Connolly², Lisa Christopher-Stine¹, Christopher Mecoli¹, Myma Albayda², Eleni Tiniakou³, Nisha Gilotra², Stefan Zimmerman² and Bharath Venkatesh², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Lutherville Timonium, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its association with poor outcomes such as heart failure and sudden cardiac death. It…
Abstract Number: 0656 • ACR Convergence 2024
Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
María del Carmen Zamora-Medina¹, Erik Cimé-Aké², Emilio G. Lazarini², Wallace Rafael A. Muñoz-Castañeda³ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Perinatología "Isidro Espinoza de los Reyes". Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Hospital Medica Sur. Rheumatology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: Limited information about lupus myocarditis (LM) comes from small case series. The aim of our study is to describe and compare clinical characteristics, cardiac…
Abstract Number: 0996 • ACR Convergence 2024
Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition
Enelle Mevorach, Adi Tabib and Dror Mevorach, Hadassah-University Hospital, Jerusalem, Israel
Background/Purpose: Following Pfizer-BioNTech BNT162b2 vaccine authorization, Israel initiated a nationwide COVID-19 vaccination campaign. The vaccine caused a higher incidence of myocarditis in young males. Here,…
Abstract Number: 1165 • ACR Convergence 2024
Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Julie Paik¹, Kevin Bermea², Carolina Duque³, Monica Mugnier³ and Luigi Adamo¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Cardiology, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Cardiac involvement, such as myocarditis, in idiopathic inflammatory myopathies (IIM) is a negative prognostic factor associated with increased mortality. The gold standard for myocarditis…
Abstract Number: 1995 • ACR Convergence 2024
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
Kaitlin McCarter¹, Xiaosong Wang², Senada Arabelovic¹, Nicole LeBoeuf¹, Elizabeth Buchbinder³, Lydia Gedmintas¹, Lindsey MacFarlane⁴, Deepak Rao⁵, Nancy Shadick², Elad Sharon³, Brittany Weber⁶, Anju Nohria¹, Ellen Gravallese⁷ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Brigham and Women's Hospital, Hanover, NH, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) antagonize CTLA-4, PD-1, PD-L1, and Lag-3 to stimulate the immune system to treat cancer but may also cause immune-related adverse…
Abstract Number: 2372 • ACR Convergence 2024
Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Yoo Jin Kim¹, Jana Lovell¹, Alaa Diab¹, Laurence Magder², Daniel Goldman³, Michelle Petri³, Luigi Adamo¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Baltimore, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE). In the general population, pericarditis commonly recurs (~30%), likely due to immune-mediated…
Abstract Number: 0661 • ACR Convergence 2023
Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study
Nafsika Gerolymatou¹, NIck Koletsos¹, Aliki Venetsanopoulou², Anastasia Giantsouli³, Sophie Mavrogeni⁴ and PARASKEVI VOULGARI⁵, ¹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²Medical School of Ioannina, Ioannina, Greece, ³Radiology Department, University Hospital of Ioannina, Ioannina, Greece, ⁴Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, University of Ioannina, Ioannina, Greece
Background/Purpose: Myocardial involvement is a significant contributor to mortality in patients with Systemic Sclerosis (SSc). The objective of this study was to analyze the clinical…
Abstract Number: 0854 • ACR Convergence 2023
Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Martin Dutertre¹, Gregory Pugnet², Claire De Moreuil³, Bernard Bonnotte⁴, YGAL BENHAMOU⁵, Dominique Chauveau⁶, Elisabeth Diot⁷, Pierre Duffau⁸, Nicolas Limal⁹, Antoine Néel¹⁰, GEOFFREY URBANSKI¹¹, Noémie Jourde-Chiche¹², Nicolas MARTIN SILVA¹³, Francois Maurier¹⁴, Arsène Mekinian¹⁵, Nicolas Schleinitz¹⁶, Felix ackermann¹⁷, Anne-Laure Fauchais¹⁸, Antoine Froissart¹⁹, Thomas Le Gallou²⁰, Yurdagul Uzunhan²¹, Jean-Francois Viallard²², Alice Berezne²³, laurent chiche²⁴, Bruno Crestani²⁵, Guillaume Direz²⁶, Cecile-Audrey DUREL²⁷, Pascal Godmer²⁸, Jean-Emmanuel Kahn²⁹, Marc Lambert³⁰, Mathilde de Menthon¹, Thomas Quemeneur³¹, Jacques Cadranel¹, Pierre Charles³², Antoine Dossier¹, Loic Guillevin³³, Xavier Puéchal³⁴ and Benjamin Terrier³⁵, ¹AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³CHU de Brest, Brest, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁵rouen university hospital, Rouen, France, ⁶Hôpital Le Tripode, Bordeaux, France, ⁷Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹AP-HP, Créteil, France, ¹⁰CHU de Nantes, Nantes, France, ¹¹CHU Angers, Angers, France, ¹²AP-HM, Marseille, France, ¹³CHU Caen, Caen, France, ¹⁴Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁵Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁶Aix Marseille university, AP-HM, Marseille, France, ¹⁷Hôpital Foch, Suresnes, France, ¹⁸Dupuytren Hospital, Limoges, France, ¹⁹CHI Créteil, Créteil, France, ²⁰CHU Rennes, Rennes, France, ²¹AP-HP, Bobigny, France, ²²CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²³CH Annecy, Annecy, France, ²⁴Hopital Europeen, Marseille, France, ²⁵Hopital Bichat, Paris University, Paris, France, ²⁶CH Le Mans, Le Mans, France, ²⁷Hospices Civils de Lyon, Lyon, France, ²⁸CH Bretagne Atlantique, Vannes, France, ²⁹AP-HP, Suresnes Cedex, France, ³⁰CHRU Lille, Lille, France, ³¹CH Valenciennes, Valenciennes, France, ³²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ³³University Paris Descartes, Paris, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…
Abstract Number: 1171 • ACR Convergence 2023
Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Caoilfhionn M. Connolly¹, Jana Lovell², Melody Chung³, Brittany Adler², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli¹, Stefan Zimmerman², Lisa Christopher-Stine², Nisha Gilotra² and Julie Paik², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Kaiser Permanante, Baltimore, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Selene Rubino¹, Grant Cannon², Brian Sauer³, Jorge Rojas Jr⁴, Greg Stoddard¹, Gary Kunkel¹, Jessica A Walsh⁵, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Puget Sound VA and University of Utah, Seattle, WA, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…
Abstract Number: 0171 • ACR Convergence 2022
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
Matilde Bandeira¹, Eduardo Dourado¹, Ana Teresa Melo¹, Patricia Martins², Vanessa Fraga³, José Luís Ferraro⁴, André Saraiva⁵, Marlene Sousa⁶, Hugo Parente⁷, Catarina Soares⁸, Ana Margarida Correia⁹, Diogo Esperança Almeida⁹, Sara Paiva Dinis¹⁰, Ana Pinto¹¹, Filipe Pinheiro¹², Maria Rato¹², Tiago Beirão¹³, Beatriz Samões¹³, Bernardo Santos¹⁴, Carolina Mazeda¹⁵, Ana Teodósio Chícharo¹⁶, Margarida Faria¹⁷, Agna Neto¹⁷, Helena Lourenço¹⁸, Luísa Brites¹⁹, Marília Rodrigues¹⁹, Joana Silva-Dinis²⁰, João Madruga-Dias²¹, Filipe Araújo²², Nádia Martins²³, Maura Couto²³, Ana Valido²⁴, Maria José Santos²⁵, Sofia Barreira¹, João Eurico Fonseca¹ and Raquel Campanilho-Marques¹, ¹Serviço de Reumatologia, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa (CAML), Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisboa, Portugal, ²Rheumatology department, Centro Hospitalar e Universitário de Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³Serviço de Reumatologia, Hospital Beatriz Ângelo, Almada, Portugal, ⁴Serviço de Reumatologia, Hospital Beatriz Ângelo, Loures, Portugal, ⁵Rheumatology department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁶Serviço de Reumatologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ⁷Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁸Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ⁹Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, ¹⁰Rheumatology department, Unidade Local de Saúde da Guarda - Hospital Sousa Martins, Guarda, Portugal, ¹¹Local Health Unit of Guarda, Barcelos, Portugal, ¹²Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ¹³Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ¹⁴Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar Baixo Vouga, Ovar, Portugal, ¹⁶Serviço de Reumatologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹⁷Serviço de Reumatologia, Hospital Nélio Mendonça, Serviços de Saúde da Região Autónoma da Madeira, Funchal, Portugal, ¹⁸Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ¹⁹Serviço de Reumatologia, Centro Hospitalar de Leiria, Leiria, Portugal, Leiria, Portugal, ²⁰Serviço de Reumatologia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal, ²¹Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ²²Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ²³Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ²⁴Serviço de Reumatologia, Unidade Local de Saúde do Litoral Alentejano, Santiago do Cacém, Portugal, ²⁵Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare disorders that can affect the heart. It is unclear which patients are at higher risk.…
Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Kassidy Banford¹, hannah Bulgart¹, Shane Bruckner², Stacy Ardoin³, Noah Weisleder² and Wael Jarjour², ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³The Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.